PD-217,014
Tools
Actions
General
Print/export
In other projects
Appearance
From Wikipedia, the free encyclopedia
Chemical compound
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H17NO2 |
Molar mass | 183.251 g·mol−1 |
3D model (JSmol) | |
| |
|
PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.[1]
References
[edit]Calcium |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||